New York, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global ADME-Toxicology Testing Industry" - https://www.reportlinker.com/p01375382/?utm_source=GNW
Absorption, distribution, metabolism, and excretion individually affect the pharmacological activity and performance of the compound as a medicine, as these features control the level of drug interaction with the tissues. The global ADME toxicity tests market is poised to grow significantly due to the tests for late-stage drug failures as they can help in saving valuable time and investment in drug development. Major factors driving growth in the market include growing demand from pharmaceutical developers and biotechnology companies due to benefits of reduced cost involved in drug discovery and development process as well as reduced time frame for new drug development. Market prospects are also favored by technological advancements such as in silico technologies, which are increasingly being used owing to their ability to deliver rapid results. Drug developers are increasingly focusing on ADME and toxicology properties for assessing the efficacy and safety profile of drug candidates, which represent key components for a regulatory approval. These insights allow companies to decide about further progress as well as file for regulatory approval. The development of software that could automatically calculate ADME is contributing to testing with the use of new cell-based in vitro assays over the traditional in vivo experiments.
Amid the COVID-19 crisis, the global market for ADME-Toxicology Testing estimated at US$6 Billion in the year 2020, is projected to reach a revised size of US$11.1 Billion by 2026, growing at a CAGR of 10.9% over the analysis period. Cell Culture, one of the segments analyzed in the report, is projected to grow at a 13.4% CAGR to reach US$5.9 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the High Throughput Screening segment is readjusted to a revised 7.6% CAGR for the next 7-year period. This segment currently accounts for a 28.9% share of the global ADME-Toxicology Testing market. Cell culture technology is popularly harnessed for the development of oral solutions for several infectious diseases. 3D cell cultures are gaining significance as they can display visual results and can help in testing lower volumes. HCS is rapidly emerging as an effective screening technology due to features such as high throughput and significant data quantity, enabled by advancements in robotics, instrumentation, image and data analysis software, storage and management tools. HCS-based strategies have today become a key part of preclinical drug testing, systems biology, and personalized medicine.
The U.S. Market is Estimated at $3.4 Billion in 2021, While China is Forecast to Reach $856.6 Million by 2026
The ADME-Toxicology Testing market in the U.S. is estimated at US$3.4 Billion in the year 2021. The country currently accounts for a 49.5% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$856.6 Million in the year 2026 trailing a CAGR of 15.4% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 12.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.3% CAGR while Rest of European market (as defined in the study) will reach US$966.9 Million by the end of the analysis period. The US and Europe represent key markets due to the presence of large pharmaceutical companies. The considerable research funding for toxicology testing and cell cultures being increasingly deployed in drug discovery drive growth in the US market.
Molecular Imaging Segment to Reach $1.9 Billion by 2026
In the global Molecular Imaging segment, USA, Canada, Japan, China and Europe will drive the 9.8% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$974.7 Million in the year 2020 will reach a projected size of US$1.8 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$122.7 Million by the year 2026.
Select Competitors (Total 79 Featured)
- Agilent Technologies, Inc.
- Beckman Coulter, Inc.
- BioreclamationIVT, LLC
- CompuDrug International, Inc.
- Cyprotex PLC.
- Eurofins ADME BIOANALYSES SAS
- Molecular Discovery Ltd.
- MultiCASE, Inc.
- PerkinElmer, Inc.
- Pharmaron, Inc.
- Promega Corporation
- Simulations Plus, Inc.
- Taconic Biosciences, Inc.
- Takara Bio Europe AB
- Tecan Group Ltd.
- Thermo Fisher Scientific, Inc.
Read the full report: https://www.reportlinker.com/p01375382/?utm_source=GNW
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
ADME-Tox: An Introduction
A Prelude to ADME Toxicology Testing
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is
the World Economy Headed in 2021
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual
% Change) for 2020 through 2022
COVID-19 Impact on Adme Toxicology Testing Market
Global Market Prospects and Growth Drivers
Drug Makers Bet on ADME & Toxicology Testing to Improve Success
Rate for Potential Drug Candidates
Cell Culture Holds a Major Share of the Market
North America and Europe Dominate, Asia-Pacific Witnesses Rapid
Growth
Competition
Recent Market Activity
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increased Need to Check Late-Stage Drug Failures Drives Market
Growth
EXHIBIT 2: Steady Increase in Average Drug Development Cost and
Efforts to Mitigate Late-Stage Drug Failure Rates Highlights
the Role of ADME-Toxicology Testing: Average Cost of Drug
Development (in US$ Billion) in the US since 1980s
Impact of ADME-Tox Screening on New Drug Discovery
EXHIBIT 3: Phase-I Clinical Trial Failures Before and After the
Advent of Preclinical ADME/Pharmacokinetics
EXHIBIT 4: Factors Leading to Failure of Drugs in Phase III
Clinical Trials: Percentage Breakdown of Number of Cases for
Efficacy, Pharmacokinetics, Toxicity and Others
EXHIBIT 5: Drug Withdrawals Due to Toxicity Issues (1990-early
2010s): Percentage Share Breakdown of Number of Drugs
Withdrawn Due to Cardiotoxicity, Hepatotoxicity and Others
Pharma Industry Renews Focus on Cost Optimization
EXHIBIT 6: Global Pharmaceutical R&D Spending (US$ Billion) for
the Years 2011 through 2020
EXHIBIT 7: New FDA Approvals (2010-2020): Breakdown of Number
of Approvals by Type for New Molecular Entity (NME) and
Biologic License Application (BLA) Approvals
China and India: Hot Spots for R&D Investment
EXHIBIT 8: World R&D Market by Geographic Region (2020):
Percentage Breakdown of R&D Spending for Asia, Europe, Middle
East & Africa, North America and South America
Growth Momentum Shifts Away from In Vivo Technologies; In Vitro
Technologies Lead the Charge
Growing Prominence of Cell-based Assays in Drug Discovery and
ADME Analysis
EXHIBIT 9: Global Cell-based Assays Market by Segment (2020):
Percentage Share Breakdown of Value Sales for Consumables,
Instruments, Software, and Services
EXHIBIT 10: Global Market for Cell-based Assays by End-User:
(2020): Percentage Share Breakdown of Value Sales for Pharma &
Biotech Companies, Government & Academic Institutes, CROs,
and Others
EXHIBIT 11: World Cell-based Assays Market by Application:
(2020): Percentage Breakdown of Revenue for ADME, Basic
Research and Drug Discovery
Major Types of Cell-Based HTS Assays for Drug Screening
Cell-based Assays in HTS and UHTS
Innovation in Screening Guarantees Success for Drug Discovery
Programs
High-Content Screening (HCS) - An Expanding Technology in Cell -
Based Assays
High Content Screening - Key Application Areas
HCS Market Ripe with Growth Opportunity
HCS vs. HTS
Increasing Use of Cell-Based Assays over Other Methods in
Toxicity Testing
3D Cell Culture Technology to Put a New Spin on In Vitro Cell
Analyses
CDER?s DARS 2?Microphysiological 3D Cell Culture Platforms as
Drug Development Tools
Rising Investment in Proteomics R&D Drive Cell-based Assays Market
Automated Multiplexing Platforms Present Growth Opportunities
Automation of Cell-based Assays: A Growing Trend
In-Silico ADME Emerge as Compelling Drug Discovery &
Development Tool
Advantages of Using In Silico Approaches
Personalized Treatments & Computational Tools: Intriguing
Facets of ADME R&D
ADME Pharmacogenomics to Power Personalized Treatments
ADME Research & Emerging Computational Tools
Omics Technology to Witness Rapid Growth
Adoption of Omics-based Technologies
In Vitro 3D Organoid Models to Meet ADME-Toxicity Testing Needs
Limitations of Traditional in vitro Cellular Models
Organoids Technology?Advanced in vitro 3D Platforms for More
Physiologically Relevant Modeling
Stem Cells Exude Great Potential in Drug Toxicity Testing
Global Market for Stem Cell-Assays
Functional Assays: An Effective Way of Predicting Specific
Toxic Effects
GPCR Targets to Drive Growth in Functional Cell Assay Market
Molecular Imaging and ADME
Organ-on-a-Chip Technology Gains Momentum in ADME Toxicology
Testing
Technological Advancements in ADME Toxicology Testing
4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for ADME-Toxicology
Testing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 2: World Historic Review for ADME-Toxicology Testing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 3: World 15-Year Perspective for ADME-Toxicology Testing
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2021 & 2027
Table 4: World Current & Future Analysis for Cell Culture by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 5: World Historic Review for Cell Culture by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 6: World 15-Year Perspective for Cell Culture by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 7: World Current & Future Analysis for High Throughput
Screening by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 8: World Historic Review for High Throughput Screening by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 9: World 15-Year Perspective for High Throughput
Screening by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2021 &
2027
Table 10: World Current & Future Analysis for Molecular Imaging
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 11: World Historic Review for Molecular Imaging by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 12: World 15-Year Perspective for Molecular Imaging by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 13: World Current & Future Analysis for OMICS by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 14: World Historic Review for OMICS by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 15: World 15-Year Perspective for OMICS by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 16: World Current & Future Analysis for Other
Technologies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 17: World Historic Review for Other Technologies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 18: World 15-Year Perspective for Other Technologies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 19: World Current & Future Analysis for Cellular Assay by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 20: World Historic Review for Cellular Assay by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 21: World 15-Year Perspective for Cellular Assay by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 22: World Current & Future Analysis for Biochemical Assay
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 23: World Historic Review for Biochemical Assay by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 24: World 15-Year Perspective for Biochemical Assay by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 25: World Current & Future Analysis for Ex-Vivo by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 26: World Historic Review for Ex-Vivo by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 27: World 15-Year Perspective for Ex-Vivo by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 28: World Current & Future Analysis for In Silica by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 29: World Historic Review for In Silica by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 30: World 15-Year Perspective for In Silica by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2021 & 2027
Table 31: World Current & Future Analysis for Systemic Toxicity
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 32: World Historic Review for Systemic Toxicity by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 33: World 15-Year Perspective for Systemic Toxicity by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 34: World Current & Future Analysis for Renal Toxicity by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 35: World Historic Review for Renal Toxicity by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 36: World 15-Year Perspective for Renal Toxicity by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 37: World Current & Future Analysis for Hepatotoxicity by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 38: World Historic Review for Hepatotoxicity by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 39: World 15-Year Perspective for Hepatotoxicity by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 40: World Current & Future Analysis for Neurotoxicity by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR
Table 41: World Historic Review for Neurotoxicity by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR
Table 42: World 15-Year Perspective for Neurotoxicity by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
Table 43: World Current & Future Analysis for Other
Applications by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR
Table 44: World Historic Review for Other Applications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 45: World 15-Year Perspective for Other Applications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2021 & 2027
III. MARKET ANALYSIS
UNITED STATES
Table 46: USA Current & Future Analysis for ADME-Toxicology
Testing by Technology - Cell Culture, High Throughput
Screening, Molecular Imaging, OMICS and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 47: USA Historic Review for ADME-Toxicology Testing by
Technology - Cell Culture, High Throughput Screening, Molecular
Imaging, OMICS and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 48: USA 15-Year Perspective for ADME-Toxicology Testing
by Technology - Percentage Breakdown of Value Sales for Cell
Culture, High Throughput Screening, Molecular Imaging, OMICS
and Other Technologies for the Years 2012, 2021 & 2027
Table 49: USA Current & Future Analysis for ADME-Toxicology
Testing by Method - Cellular Assay, Biochemical Assay, Ex-Vivo
and In Silica - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 50: USA Historic Review for ADME-Toxicology Testing by
Method - Cellular Assay, Biochemical Assay, Ex-Vivo and In
Silica Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 51: USA 15-Year Perspective for ADME-Toxicology Testing
by Method - Percentage Breakdown of Value Sales for Cellular
Assay, Biochemical Assay, Ex-Vivo and In Silica for the Years
2012, 2021 & 2027
Table 52: USA Current & Future Analysis for ADME-Toxicology
Testing by Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 53: USA Historic Review for ADME-Toxicology Testing by
Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 54: USA 15-Year Perspective for ADME-Toxicology Testing
by Application - Percentage Breakdown of Value Sales for
Systemic Toxicity, Renal Toxicity, Hepatotoxicity,
Neurotoxicity and Other Applications for the Years 2012, 2021 &
2027
CANADA
Table 55: Canada Current & Future Analysis for ADME-Toxicology
Testing by Technology - Cell Culture, High Throughput
Screening, Molecular Imaging, OMICS and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 56: Canada Historic Review for ADME-Toxicology Testing by
Technology - Cell Culture, High Throughput Screening, Molecular
Imaging, OMICS and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 57: Canada 15-Year Perspective for ADME-Toxicology
Testing by Technology - Percentage Breakdown of Value Sales for
Cell Culture, High Throughput Screening, Molecular Imaging,
OMICS and Other Technologies for the Years 2012, 2021 & 2027
Table 58: Canada Current & Future Analysis for ADME-Toxicology
Testing by Method - Cellular Assay, Biochemical Assay, Ex-Vivo
and In Silica - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 59: Canada Historic Review for ADME-Toxicology Testing by
Method - Cellular Assay, Biochemical Assay, Ex-Vivo and In
Silica Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 60: Canada 15-Year Perspective for ADME-Toxicology
Testing by Method - Percentage Breakdown of Value Sales for
Cellular Assay, Biochemical Assay, Ex-Vivo and In Silica for
the Years 2012, 2021 & 2027
Table 61: Canada Current & Future Analysis for ADME-Toxicology
Testing by Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 62: Canada Historic Review for ADME-Toxicology Testing by
Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 63: Canada 15-Year Perspective for ADME-Toxicology
Testing by Application - Percentage Breakdown of Value Sales
for Systemic Toxicity, Renal Toxicity, Hepatotoxicity,
Neurotoxicity and Other Applications for the Years 2012, 2021 &
2027
JAPAN
Table 64: Japan Current & Future Analysis for ADME-Toxicology
Testing by Technology - Cell Culture, High Throughput
Screening, Molecular Imaging, OMICS and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 65: Japan Historic Review for ADME-Toxicology Testing by
Technology - Cell Culture, High Throughput Screening, Molecular
Imaging, OMICS and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 66: Japan 15-Year Perspective for ADME-Toxicology Testing
by Technology - Percentage Breakdown of Value Sales for Cell
Culture, High Throughput Screening, Molecular Imaging, OMICS
and Other Technologies for the Years 2012, 2021 & 2027
Table 67: Japan Current & Future Analysis for ADME-Toxicology
Testing by Method - Cellular Assay, Biochemical Assay, Ex-Vivo
and In Silica - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 68: Japan Historic Review for ADME-Toxicology Testing by
Method - Cellular Assay, Biochemical Assay, Ex-Vivo and In
Silica Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 69: Japan 15-Year Perspective for ADME-Toxicology Testing
by Method - Percentage Breakdown of Value Sales for Cellular
Assay, Biochemical Assay, Ex-Vivo and In Silica for the Years
2012, 2021 & 2027
Table 70: Japan Current & Future Analysis for ADME-Toxicology
Testing by Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 71: Japan Historic Review for ADME-Toxicology Testing by
Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 72: Japan 15-Year Perspective for ADME-Toxicology Testing
by Application - Percentage Breakdown of Value Sales for
Systemic Toxicity, Renal Toxicity, Hepatotoxicity,
Neurotoxicity and Other Applications for the Years 2012, 2021 &
2027
CHINA
Table 73: China Current & Future Analysis for ADME-Toxicology
Testing by Technology - Cell Culture, High Throughput
Screening, Molecular Imaging, OMICS and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 74: China Historic Review for ADME-Toxicology Testing by
Technology - Cell Culture, High Throughput Screening, Molecular
Imaging, OMICS and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 75: China 15-Year Perspective for ADME-Toxicology Testing
by Technology - Percentage Breakdown of Value Sales for Cell
Culture, High Throughput Screening, Molecular Imaging, OMICS
and Other Technologies for the Years 2012, 2021 & 2027
Table 76: China Current & Future Analysis for ADME-Toxicology
Testing by Method - Cellular Assay, Biochemical Assay, Ex-Vivo
and In Silica - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 77: China Historic Review for ADME-Toxicology Testing by
Method - Cellular Assay, Biochemical Assay, Ex-Vivo and In
Silica Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 78: China 15-Year Perspective for ADME-Toxicology Testing
by Method - Percentage Breakdown of Value Sales for Cellular
Assay, Biochemical Assay, Ex-Vivo and In Silica for the Years
2012, 2021 & 2027
Table 79: China Current & Future Analysis for ADME-Toxicology
Testing by Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 80: China Historic Review for ADME-Toxicology Testing by
Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR
Table 81: China 15-Year Perspective for ADME-Toxicology Testing
by Application - Percentage Breakdown of Value Sales for
Systemic Toxicity, Renal Toxicity, Hepatotoxicity,
Neurotoxicity and Other Applications for the Years 2012, 2021 &
2027
EUROPE
Table 82: Europe Current & Future Analysis for ADME-Toxicology
Testing by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR
Table 83: Europe Historic Review for ADME-Toxicology Testing by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Table 84: Europe 15-Year Perspective for ADME-Toxicology
Testing by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2012, 2021 & 2027
Table 85: Europe Current & Future Analysis for ADME-Toxicology
Testing by Technology - Cell Culture, High Throughput
Screening, Molecular Imaging, OMICS and Other Technologies -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR
Table 86: Europe Historic Review for ADME-Toxicology Testing by
Technology - Cell Culture, High Throughput Screening, Molecular
Imaging, OMICS and Other Technologies Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR
Table 87: Europe 15-Year Perspective for ADME-Toxicology
Testing by Technology - Percentage Breakdown of Value Sales for
Cell Culture, High Throughput Screening, Molecular Imaging,
OMICS and Other Technologies for the Years 2012, 2021 & 2027
Table 88: Europe Current & Future Analysis for ADME-Toxicology
Testing by Method - Cellular Assay, Biochemical Assay, Ex-Vivo
and In Silica - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR
Table 89: Europe Historic Review for ADME-Toxicology Testing by
Method - Cellular Assay, Biochemical Assay, Ex-Vivo and In
Silica Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR
Table 90: Europe 15-Year Perspective for ADME-Toxicology
Testing by Method - Percentage Breakdown of Value Sales for
Cellular Assay, Biochemical Assay, Ex-Vivo and In Silica for
the Years 2012, 2021 & 2027
Table 91: Europe Current & Future Analysis for ADME-Toxicology
Testing by Application - Systemic Toxicity, Renal Toxicity,
Hepatotoxicity, Neurotoxicity and Other Applications -
Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p01375382/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________
